ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial

In all 200 suffers were recruited to the trial and all of them have now past the three month stage.

ImmuPharma PLC (LON:IMM) said more than 90% of the patients on its phase III clinical study of Lupuzor, for the autoimmune disease lupus, six months through the process.

In all 200 suffers were recruited to the trial and all of them have now past the three month stage.

A total of 46 patients, or just under a quarter, have completed the year-long assessment, while 40% have passed nine-months.

ImmuPharma said it remains on track to provide top-line results in the first quarter of next year.

The data was provided ahead of an investor update to be held in London that will be coupled with the company’s annual meeting later Friday.

“As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor is being administered to greater numbers of patients over a longer period of time,” chairman Tim McCarthy said.

Source: http://www.proactiveinvestors.co.uk/companies/news/180096/immupharma-says-90-of-patients-have-pass-six-month-milestone-on-key-lupus-trial-180096.html

[wdps id=”6″]

Share This

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.